Wells Fargo
MRTX

Wells Fargo’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Wells Fargo’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-9,665
Closed -$568K – 7819
2023
Q4 		$568K Sell
9,665
-138,782
-93% -$7.8M ﹤0.01% 3778
2023
Q3 		$6.47M Buy
148,447
+39,774
+37% +$1.42M ﹤0.01% 1929
2023
Q2 		$3.93M Buy
108,673
+6,707
+7% +$276K ﹤0.01% 2339
2023
Q1 		$3.79M Buy
101,966
+28,324
+38% +$1.27M ﹤0.01% 2339
2022
Q4 		$3.34M Buy
73,642
+7,966
+12% +$516K ﹤0.01% 2373
2022
Q3 		$4.59M Sell
65,676
-4,642
-7% -$343K ﹤0.01% 2061
2022
Q2 		$4.72M Sell
70,318
-21,146
-23% -$1.34M ﹤0.01% 2139
2022
Q1 		$7.52M Buy
91,464
+28,547
+45% +$2.92M ﹤0.01% 2083
2021
Q4 		$9.23M Sell
62,917
-223,065
-78% -$34.6M ﹤0.01% 1944
2021
Q3 		$50.6M Sell
285,982
-39,830
-12% -$6.41M 0.01% 1051
2021
Q2 		$52.6M Buy
325,812
+1,977
+0.6% +$317K 0.01% 1035
2021
Q1 		$55.5M Buy
323,835
+23,569
+8% +$4.67M 0.01% 996
2020
Q4 		$66M Buy
300,266
+89,787
+43% +$19.4M 0.02% 835
2020
Q3 		$35M Buy
210,479
+151,780
+259% +$20.8M 0.01% 1059
2020
Q2 		$6.7M Buy
58,699
+13,365
+29% +$1.3M ﹤0.01% 2189
2020
Q1 		$3.48M Buy
45,334
+5,073
+13% +$455K ﹤0.01% 2536
2019
Q4 		$5.19M Sell
40,261
-222,207
-85% -$21.4M ﹤0.01% 2539
2019
Q3 		$20.4M Sell
262,468
-5,515
-2% -$518K 0.01% 1424
2019
Q2 		$27.6M Sell
267,983
-77,366
-22% -$6.02M 0.01% 1262
2019
Q1 		$25.3M Sell
345,349
-7,491
-2% -$510K 0.01% 1299
2018
Q4 		$15M Buy
352,840
+89,959
+34% +$3.58M 0.01% 1577
2018
Q3 		$12.4M Buy
262,881
+252,428
+2,415% +$14.1M ﹤0.01% 1900
2018
Q2 		$515K Buy
10,453
+8,132
+350% +$307K ﹤0.01% 4430
2018
Q1 		$71K Buy
2,321
+1,621
+232% +$45K ﹤0.01% 5447
2017
Q4 		$13K Hold
700
– – ﹤0.01% 5874
2017
Q3 		$8K Buy
+700
New +$4.05K ﹤0.01% 5932
2017
Q2 		– Sell
-14,224
Closed -$74K – 6513
2017
Q1 		$74K Buy
14,224
+11,300
+386% +$61.9K ﹤0.01% 5318
2016
Q4 		$14K Sell
2,924
-500
-15% -$2.72K ﹤0.01% 5716
2016
Q3 		$22K Buy
3,424
+500
+17% +$2.66K ﹤0.01% 5579
2016
Q2 		$16K Sell
2,924
-1,412
-33% -$22.5K ﹤0.01% 5550
2016
Q1 		$92K Buy
4,336
+593
+16% +$13.3K ﹤0.01% 4891
2015
Q4 		$119K Buy
3,743
+75
+2% +$2.65K ﹤0.01% 4799
2015
Q3 		$126K Sell
3,668
-432
-11% -$13.1K ﹤0.01% 4731
2015
Q2 		$129K Buy
4,100
+1,763
+75% +$52K ﹤0.01% 4877
2015
Q1 		$69K Buy
2,337
+1,327
+131% +$31.1K ﹤0.01% 4895
2014
Q4 		$19K Buy
1,010
+3
+0.3% +$51 ﹤0.01% 5387
2014
Q3 		$18K Sell
1,007
-180
-15% -$3.36K ﹤0.01% 5359
2014
Q2 		$24K Sell
1,187
-2,372
-67% -$45.8K ﹤0.01% 5301
2014
Q1 		$68K Buy
3,559
+2,882
+426% +$59.9K ﹤0.01% 4823
2013
Q4 		$11K Hold
677
– – ﹤0.01% 5178
2013
Q3 		$10K Buy
+677
New +$6.65K ﹤0.01% 5123

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Wells Fargo's MRTX Position: Q1 2024 in Review

Wells Fargo sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 9,665 shares — an estimated $568K sold.

Wells Fargo first reported a position in MRTX in Q3 2013 and held it in 41 quarters. The position peaked at $66M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Wells Fargo reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Wells Fargo sold 9,665 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $568K.
  • Wells Fargo first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2013 and held it in 41 quarters.
  • Wells Fargo's Mirati Therapeutics, Inc. Common Stock position peaked at $66M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.